
Chameli Das
Examiner (ID: 7327, Phone: (571)272-3696 , Office: P/2197 )
| Most Active Art Unit | 2197 |
| Art Unit(s) | 2197, 2196, 2762, 2122, 2192 |
| Total Applications | 1155 |
| Issued Applications | 1034 |
| Pending Applications | 35 |
| Abandoned Applications | 96 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 6561873
[patent_doc_number] => 20100272734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-10-28
[patent_title] => 'COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH'
[patent_app_type] => utility
[patent_app_number] => 12/767509
[patent_app_country] => US
[patent_app_date] => 2010-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 33600
[patent_no_of_claims] => 51
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0272/20100272734.pdf
[firstpage_image] =>[orig_patent_app_number] => 12767509
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/767509 | Compositions and methods for increasing muscle growth | Apr 25, 2010 | Issued |
Array
(
[id] => 7807163
[patent_doc_number] => 20120058116
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-03-08
[patent_title] => 'FGFR1C ANTIBODY COMBINATIONS'
[patent_app_type] => utility
[patent_app_number] => 13/265887
[patent_app_country] => US
[patent_app_date] => 2010-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 12357
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0058/20120058116.pdf
[firstpage_image] =>[orig_patent_app_number] => 13265887
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/265887 | FGFR1C ANTIBODY COMBINATIONS | Apr 21, 2010 | Abandoned |
Array
(
[id] => 6234909
[patent_doc_number] => 20100266613
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-10-21
[patent_title] => 'ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES'
[patent_app_type] => utility
[patent_app_number] => 12/761745
[patent_app_country] => US
[patent_app_date] => 2010-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 24254
[patent_no_of_claims] => 48
[patent_no_of_ind_claims] => 14
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0266/20100266613.pdf
[firstpage_image] =>[orig_patent_app_number] => 12761745
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/761745 | Anti-TNF-α antibodies and their uses | Apr 15, 2010 | Issued |
Array
(
[id] => 8220800
[patent_doc_number] => 20120135005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-31
[patent_title] => 'ANTI-TNF-a ANTIBODIES AND THEIR USES'
[patent_app_type] => utility
[patent_app_number] => 13/264983
[patent_app_country] => US
[patent_app_date] => 2010-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 26040
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13264983
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/264983 | ANTI-TNF-a ANTIBODIES AND THEIR USES | Apr 15, 2010 | Abandoned |
Array
(
[id] => 6266473
[patent_doc_number] => 20100298232
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-11-25
[patent_title] => 'Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 12/799024
[patent_app_country] => US
[patent_app_date] => 2010-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 39
[patent_no_of_words] => 24946
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0298/20100298232.pdf
[firstpage_image] =>[orig_patent_app_number] => 12799024
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/799024 | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof | Apr 15, 2010 | Issued |
Array
(
[id] => 6320557
[patent_doc_number] => 20100196383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-08-05
[patent_title] => 'Connective Tissue Growth Factor (CTGF-3)'
[patent_app_type] => utility
[patent_app_number] => 12/761083
[patent_app_country] => US
[patent_app_date] => 2010-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 20889
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0196/20100196383.pdf
[firstpage_image] =>[orig_patent_app_number] => 12761083
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/761083 | Connective tissue growth factor (CTGF-3) polypeptides | Apr 14, 2010 | Issued |
Array
(
[id] => 8141653
[patent_doc_number] => 20120094935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-04-19
[patent_title] => 'METHODS FOR CREATING OR IDENTIFYING COMPOUNDS THAT BIND TUMOR NECROSIS FACTOR ALPHA'
[patent_app_type] => utility
[patent_app_number] => 13/263308
[patent_app_country] => US
[patent_app_date] => 2010-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 385627
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0094/20120094935.pdf
[firstpage_image] =>[orig_patent_app_number] => 13263308
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/263308 | METHODS FOR CREATING OR IDENTIFYING COMPOUNDS THAT BIND TUMOR NECROSIS FACTOR ALPHA | Apr 8, 2010 | Abandoned |
Array
(
[id] => 8675666
[patent_doc_number] => 08383780
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-02-26
[patent_title] => 'Antibodies to TGFβ'
[patent_app_type] => utility
[patent_app_number] => 12/724347
[patent_app_country] => US
[patent_app_date] => 2010-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 21326
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12724347
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/724347 | Antibodies to TGFβ | Mar 14, 2010 | Issued |
Array
(
[id] => 8126725
[patent_doc_number] => 20120087910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-04-12
[patent_title] => 'SPARC ANGIOGENIC DOMAIN AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 13/256135
[patent_app_country] => US
[patent_app_date] => 2010-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 15533
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0087/20120087910.pdf
[firstpage_image] =>[orig_patent_app_number] => 13256135
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/256135 | SPARC ANGIOGENIC DOMAIN AND METHODS OF USE | Mar 10, 2010 | Abandoned |
Array
(
[id] => 6635998
[patent_doc_number] => 20100226928
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-09-09
[patent_title] => 'Lyophilised Antibody Formulation'
[patent_app_type] => utility
[patent_app_number] => 12/718387
[patent_app_country] => US
[patent_app_date] => 2010-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8240
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0226/20100226928.pdf
[firstpage_image] =>[orig_patent_app_number] => 12718387
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/718387 | Lyophilised Antibody Formulation | Mar 4, 2010 | Abandoned |
Array
(
[id] => 6289933
[patent_doc_number] => 20100158918
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-24
[patent_title] => 'Polypeptides and polynucleotides encoding same'
[patent_app_type] => utility
[patent_app_number] => 12/714930
[patent_app_country] => US
[patent_app_date] => 2010-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 35
[patent_no_of_words] => 36004
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0158/20100158918.pdf
[firstpage_image] =>[orig_patent_app_number] => 12714930
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/714930 | Polypeptides and polynucleotides encoding same | Feb 28, 2010 | Abandoned |
Array
(
[id] => 9850400
[patent_doc_number] => 08952130
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-02-10
[patent_title] => 'Designer ligands of TGF-β superfamily'
[patent_app_type] => utility
[patent_app_number] => 12/712069
[patent_app_country] => US
[patent_app_date] => 2010-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 43885
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12712069
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/712069 | Designer ligands of TGF-β superfamily | Feb 23, 2010 | Issued |
Array
(
[id] => 7795905
[patent_doc_number] => 08124611
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-02-28
[patent_title] => 'Inhibitors of the mutant form of kit'
[patent_app_type] => utility
[patent_app_number] => 12/700106
[patent_app_country] => US
[patent_app_date] => 2010-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1834
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/124/08124611.pdf
[firstpage_image] =>[orig_patent_app_number] => 12700106
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/700106 | Inhibitors of the mutant form of kit | Feb 3, 2010 | Issued |
Array
(
[id] => 7580851
[patent_doc_number] => 20110294734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-01
[patent_title] => 'PHARMACEUTICAL COMPOSITIONS COMPRISING TGF-BETA 1 INHIBITOR PEPTIDES'
[patent_app_type] => utility
[patent_app_number] => 13/147145
[patent_app_country] => US
[patent_app_date] => 2010-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15528
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0294/20110294734.pdf
[firstpage_image] =>[orig_patent_app_number] => 13147145
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/147145 | PHARMACEUTICAL COMPOSITIONS COMPRISING TGF-BETA 1 INHIBITOR PEPTIDES | Feb 3, 2010 | Abandoned |
Array
(
[id] => 7670018
[patent_doc_number] => 20110319287
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-29
[patent_title] => 'MODULATOR ASSAY'
[patent_app_type] => utility
[patent_app_number] => 13/145248
[patent_app_country] => US
[patent_app_date] => 2010-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 10669
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13145248
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/145248 | MODULATOR ASSAY | Jan 18, 2010 | Abandoned |
Array
(
[id] => 6320444
[patent_doc_number] => 20100113363
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-05-06
[patent_title] => 'Use of GLP-1 Peptides'
[patent_app_type] => utility
[patent_app_number] => 12/651685
[patent_app_country] => US
[patent_app_date] => 2010-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 5364
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0113/20100113363.pdf
[firstpage_image] =>[orig_patent_app_number] => 12651685
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/651685 | Use of GLP-1 Peptides | Jan 3, 2010 | Abandoned |
Array
(
[id] => 7710242
[patent_doc_number] => 20120003234
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-05
[patent_title] => 'Osteoarthritis treatment'
[patent_app_type] => utility
[patent_app_number] => 13/140467
[patent_app_country] => US
[patent_app_date] => 2009-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 8811
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13140467
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/140467 | Osteoarthritis treatment | Dec 20, 2009 | Issued |
Array
(
[id] => 6614524
[patent_doc_number] => 20100099620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-04-22
[patent_title] => 'Protracted GLP-1 Compositions'
[patent_app_type] => utility
[patent_app_number] => 12/642067
[patent_app_country] => US
[patent_app_date] => 2009-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2409
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0099/20100099620.pdf
[firstpage_image] =>[orig_patent_app_number] => 12642067
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/642067 | Protracted GLP-1 Compositions | Dec 17, 2009 | Abandoned |
Array
(
[id] => 6296729
[patent_doc_number] => 20100160608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-06-24
[patent_title] => 'PROTEIN STABILIZER'
[patent_app_type] => utility
[patent_app_number] => 12/638063
[patent_app_country] => US
[patent_app_date] => 2009-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4666
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0160/20100160608.pdf
[firstpage_image] =>[orig_patent_app_number] => 12638063
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/638063 | PROTEIN STABILIZER | Dec 14, 2009 | Abandoned |
Array
(
[id] => 7487486
[patent_doc_number] => 20110236398
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-29
[patent_title] => 'Antibody Formulation'
[patent_app_type] => utility
[patent_app_number] => 13/133843
[patent_app_country] => US
[patent_app_date] => 2009-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 7346
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0236/20110236398.pdf
[firstpage_image] =>[orig_patent_app_number] => 13133843
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/133843 | Antibody Formulation | Dec 8, 2009 | Abandoned |